<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:47:15Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8449801" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8449801</identifier>
        <datestamp>2021-10-21</datestamp>
        <setSpec>clpt</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="cpt2311" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Clin Pharmacol Ther</journal-id>
              <journal-id journal-id-type="iso-abbrev">Clin Pharmacol Ther</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)1532-6535</journal-id>
              <journal-id journal-id-type="publisher-id">CPT</journal-id>
              <journal-title-group>
                <journal-title>Clinical Pharmacology and Therapeutics</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0009-9236</issn>
              <issn pub-type="epub">1532-6535</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8449801</article-id>
              <article-id pub-id-type="pmcid">PMC8449801</article-id>
              <article-id pub-id-type="pmc-uid">8449801</article-id>
              <article-id pub-id-type="pmid">34048027</article-id>
              <article-id pub-id-type="pmid">34048027</article-id>
              <article-id pub-id-type="doi">10.1002/cpt.2311</article-id>
              <article-id pub-id-type="publisher-id">CPT2311</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Article</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Articles</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early‐Stage Breast Cancer</article-title>
              </title-group>
              <contrib-group>
                <contrib id="cpt2311-cr-0001" contrib-type="author">
                  <name>
                    <surname>Cairns</surname>
                    <given-names>Junmei</given-names>
                  </name>
                  <xref rid="cpt2311-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="cpt2311-cr-0002" contrib-type="author">
                  <name>
                    <surname>Kalari</surname>
                    <given-names>Krishna R.</given-names>
                  </name>
                  <xref rid="cpt2311-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cpt2311-cr-0003" contrib-type="author">
                  <name>
                    <surname>Ingle</surname>
                    <given-names>James N.</given-names>
                  </name>
                  <xref rid="cpt2311-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="cpt2311-cr-0004" contrib-type="author">
                  <name>
                    <surname>Shepherd</surname>
                    <given-names>Lois E.</given-names>
                  </name>
                  <xref rid="cpt2311-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="cpt2311-cr-0005" contrib-type="author">
                  <name>
                    <surname>Ellis</surname>
                    <given-names>Matthew J.</given-names>
                  </name>
                  <xref rid="cpt2311-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="cpt2311-cr-0006" contrib-type="author">
                  <name>
                    <surname>Goss</surname>
                    <given-names>Paul E.</given-names>
                  </name>
                  <xref rid="cpt2311-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="cpt2311-cr-0007" contrib-type="author">
                  <name>
                    <surname>Barman</surname>
                    <given-names>Poulami</given-names>
                  </name>
                  <xref rid="cpt2311-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cpt2311-cr-0008" contrib-type="author">
                  <name>
                    <surname>Carlson</surname>
                    <given-names>Erin E.</given-names>
                  </name>
                  <xref rid="cpt2311-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cpt2311-cr-0009" contrib-type="author">
                  <name>
                    <surname>Goodnature</surname>
                    <given-names>Barbara</given-names>
                  </name>
                  <xref rid="cpt2311-aff-0007" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib id="cpt2311-cr-0010" contrib-type="author">
                  <name>
                    <surname>Goetz</surname>
                    <given-names>Matthew P.</given-names>
                  </name>
                  <xref rid="cpt2311-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="cpt2311-cr-0011" contrib-type="author">
                  <name>
                    <surname>Weinshilboum</surname>
                    <given-names>Richard M.</given-names>
                  </name>
                  <xref rid="cpt2311-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="cpt2311-cr-0012" contrib-type="author">
                  <name>
                    <surname>Gao</surname>
                    <given-names>Huanyao</given-names>
                  </name>
                  <xref rid="cpt2311-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="cpt2311-cr-0013" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Wang</surname>
                    <given-names>Liewei</given-names>
                  </name>
                  <xref rid="cpt2311-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <address>
                    <email>wang.liewei@mayo.edu</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="cpt2311-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Division of Clinical Pharmacology</named-content>
                <named-content content-type="organisation-division">Department of Molecular Pharmacology and Experimental Therapeutics</named-content>
                <institution>Mayo Clinic</institution>
                <city>Rochester</city>
                <named-content content-type="country-part">Minnesota</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cpt2311-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Division of Biomedical Statistics and Informatics</named-content>
                <named-content content-type="organisation-division">Department of Health Sciences Research</named-content>
                <institution>Mayo Clinic</institution>
                <city>Rochester</city>
                <named-content content-type="country-part">Minnesota</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cpt2311-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Division of Medical Oncology</named-content>
                <named-content content-type="organisation-division">Department of Oncology</named-content>
                <institution>Mayo Clinic</institution>
                <city>Rochester</city>
                <named-content content-type="country-part">Minnesota</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cpt2311-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <institution>Canadian Cancer Trials Group</institution>
                <city>Kingston</city>
                <named-content content-type="country-part">Ontario</named-content>
                <country country="CA">Canada</country>
              </aff>
              <aff id="cpt2311-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">Department of Medicine</named-content>
                <institution>Baylor University College of Medicine</institution>
                <city>Houston</city>
                <named-content content-type="country-part">Texas</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cpt2311-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <named-content content-type="organisation-division">Massachusetts General Hospital Cancer Center</named-content>
                <institution>Harvard University</institution>
                <city>Boston</city>
                <named-content content-type="country-part">Massachusetts</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cpt2311-aff-0007">
                <label>
                  <sup>7</sup>
                </label>
                <named-content content-type="organisation-division">Patient Advocate</named-content>
                <institution>Mayo Clinic Breast Cancer Specialized Program of Research Excellence</institution>
                <city>Rochester</city>
                <named-content content-type="country-part">Minnesota</named-content>
                <country country="US">USA</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label>
Correspondence: Liewei Wang (<email>wang.liewei@mayo.edu</email>)<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>21</day>
                <month>6</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>10</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>21</day>
                <month>6</month>
                <year>2021</year>
              </pub-date>
              <volume>110</volume>
              <issue seq="300">4</issue>
              <issue-id pub-id-type="doi">10.1002/cpt.v110.4</issue-id>
              <fpage>1038</fpage>
              <lpage>1049</lpage>
              <history>
                <date date-type="received">
                  <day>24</day>
                  <month>3</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>08</day>
                  <month>5</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; 2021 American Society for Clinical Pharmacology and Therapeutics-->
                <copyright-statement content-type="article-copyright">© 2021 The Authors. <italic toggle="yes">Clinical Pharmacology &amp; Therapeutics</italic> published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:CPT-110-1038.pdf"/>
              <abstract id="cpt2311-abs-0001">
                <p>Aromatase inhibitors (AIs) are the treatment of choice for hormone receptor–positive early breast cancer in postmenopausal women. None of the third‐generation AIs are superior to the others in terms of efficacy. We attempted to identify genetic factors that could differentiate between the effectiveness of adjuvant anastrozole and exemestane by examining single‐nucleotide polymorphism (SNP)‐treatment interaction in 4,465 patients. A group of SNPs were found to be differentially associated between anastrozole and exemestane regarding outcomes. However, they showed no association with outcome in the combined analysis. We followed up common SNPs near LY75 and GPR160 that could differentiate anastrozole from exemestane efficacy. LY75 and GPR160 participate in epithelial‐to‐mesenchymal transition and growth pathways, in both cases with SNP‐dependent variation in regulation. Collectively, these studies identified SNPs that differentiate the efficacy of anastrozole and exemestane and they suggest additional genetic biomarkers for possible use in selecting an AI for a given patient.</p>
              </abstract>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>Mayo Clinic Breast Cancer Specialized Program of Research Excellence</funding-source>
                  <award-id>P50CA116201</award-id>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>The Pharmacogenomics Research Network</funding-source>
                  <award-id>U1961388</award-id>
                </award-group>
                <award-group id="funding-0003">
                  <funding-source>the Breast Cancer Research Foundation</funding-source>
                  <award-id>U54 GM114838</award-id>
                  <award-id>BCRF‐17‐075</award-id>
                </award-group>
                <award-group id="funding-0004">
                  <funding-source>
                    <institution-wrap>
                      <institution>Canadian Cancer Society
</institution>
                      <institution-id institution-id-type="doi">10.13039/501100000521</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>U10CA77202</award-id>
                  <award-id>R01CA196648</award-id>
                  <award-id>CCS 015469</award-id>
                </award-group>
                <award-group id="funding-0005">
                  <funding-source>George M. Eisenberg Foundation for Charities</funding-source>
                </award-group>
                <award-group id="funding-0006">
                  <funding-source>Nan Sawyer Breast Cancer Fund</funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="5"/>
                <table-count count="1"/>
                <page-count count="12"/>
                <word-count count="7273"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>October 2021</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.0.8 mode:remove_FC converted:15.10.2021</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body id="cpt2311-body-0001">
            <p>
              <boxed-text position="anchor" content-type="box" id="cpt2311-blkfxd-0001">
                <caption>
                  <title>
                    <bold>Study</bold>
                    <bold>Highlights</bold>
                  </title>
                </caption>
                <p>
                  <list list-type="simple" id="cpt2311-list-0001">
                    <list-item>
                      <p>
                        <bold>WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?</bold>
                      </p>
                    </list-item>
                  </list>
                </p>
                <p>☑ None of the third‐generation aromatase inhibitors (AIs) are superior to the others in terms of efficacy. As a result, there is currently no basis upon which to choose one AI over the others as adjuvant therapy for early‐stage breast cancer.
<list list-type="simple" id="cpt2311-list-0002"><list-item><p><bold>WHAT QUESTION DID THIS STUDY ADDRESS?</bold></p></list-item></list>
</p>
                <p>☑ To identify genetic factors that could differentiate between the effectiveness of adjuvant anastrozole and exemestane.
<list list-type="simple" id="cpt2311-list-0003"><list-item><p><bold>WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?</bold></p></list-item></list>
</p>
                <p>☑ We have obtained evidence that anastrozole and exemestane have differing efficacy depending on genetic background.
<list list-type="simple" id="cpt2311-list-0004"><list-item><p><bold>HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?</bold></p></list-item></list>
</p>
                <p>☑ We identified a single‐nucleotide polymorphism biomarker panel for future individualized therapy of selected patients who might benefit from anastrozole vs. exemestane.</p>
              </boxed-text>
            </p>
            <sec sec-type="opening-section" id="cpt2311-sec-0002">
              <p>Breast cancer is the most frequent cancer diagnosed among women, impacting more than two million women each year worldwide and causing over 600,000 deaths in 2018.<xref rid="cpt2311-bib-0001" ref-type="bibr"><sup>1</sup></xref> The majority of those cases were in postmenopausal women with early‐stage estrogen receptor α (ERα)‐positive tumors for which adjuvant endocrine treatment with aromatase inhibitors (AIs), inhibitors of estrogen synthesis,<xref rid="cpt2311-bib-0002" ref-type="bibr"><sup>2</sup></xref> is the first‐line treatment. Aromatase is the enzyme responsible for the conversion of testosterone to estrone (E1) and of androstenedione to estradiol (E2). Inhibitors of aromatase were developed to block the synthesis of estrogen in peripheral tissues and, thus, as antiestrogen therapy for the treatment of ERα positive breast cancer in postmenopausal women.<xref rid="cpt2311-bib-0003" ref-type="bibr"><sup>3</sup></xref> The third‐generation AIs that are widely used in the clinic include anastrozole and letrozole, two nonsteroidal compounds, and exemestane, a steroidal aromatase inhibitor. All three of the third‐generation AIs are superior to tamoxifen in the adjuvant setting for the treatment of hormone‐dependent early breast cancer in postmenopausal women.<xref rid="cpt2311-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="cpt2311-bib-0005" ref-type="bibr"><sup>5</sup></xref>, <xref rid="cpt2311-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="cpt2311-bib-0007" ref-type="bibr"><sup>7</sup></xref> Pharmacodynamic studies have shown that letrozole more effectively suppresses plasma estradiol levels than does anastrozole in patients with advanced breast cancer,<xref rid="cpt2311-bib-0008" ref-type="bibr"><sup>8</sup></xref> but the Femara Versus Anastrozole Clinical Evaluation (FACE) trial in 4,136 patients comparing the efficacy of adjuvant anastrozole vs. letrozole head‐to‐head showed no statistically significant difference in disease‐free survival or overall survival between the treatment arms.<xref rid="cpt2311-bib-0009" ref-type="bibr"><sup>9</sup></xref> Another head‐to‐head comparison of anastrozole and exemestane in the MA.27 trial in 7,576 patients also indicated that treatment with exemestane for 5 years was not better than anastrozole for 5 years.<xref rid="cpt2311-bib-0010" ref-type="bibr"><sup>10</sup></xref> The more recent FATA‐GIM3 trial directly compared anastrozole, exemestane, and letrozole for the first time as adjuvant treatment for hormone receptor‐positive early breast cancer, and found no significant difference in disease‐free survival 5 years after the initiation of treatments among the 3 groups.<xref rid="cpt2311-bib-0011" ref-type="bibr"><sup>11</sup></xref> As a result, there is currently no basis upon which to choose one AI over the others as adjuvant therapy for early‐stage breast cancer.</p>
              <p>The “dogma” that the three AIs are essentially the same has been revisited based on our recent data showing that anastrozole, but not exemestane or letrozole, displays an association between the degree of estrogen suppression and outcomes in early breast cancer, and that anastrozole has a mechanism of action in addition to aromatase inhibition in that it is a ligand for ERα.<xref rid="cpt2311-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="cpt2311-bib-0013" ref-type="bibr"><sup>13</sup></xref> These findings have potential implications for the individualization of AIs therapy.</p>
              <p>Genomewide association studies (GWAS) have identified several genomic regions that affect risks for breast cancer recurrence in women treated with AIs.<xref rid="cpt2311-bib-0013" ref-type="bibr"><sup>13</sup></xref>, <xref rid="cpt2311-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="cpt2311-bib-0015" ref-type="bibr"><sup>15</sup></xref> However, prior studies did not systematically test whether there might be an interaction between individual AI treatment and genetic variability. In the present study, we have investigated germline genetic variation as a predictive marker for differential efficacy of the nonsteroidal AI anastrozole and the steroidal exemestane and as a prognostic marker in the adjuvant Canadian Cancer Trials Group (CCTG) MA.27 trial<xref rid="cpt2311-bib-0010" ref-type="bibr"><sup>10</sup></xref> in patients with hormone receptor‐positive early breast cancer. We found that a group of single‐nucleotide polymorphisms (SNPs) were differentially associated between anastrozole and exemestane regarding outcomes.</p>
            </sec>
            <sec sec-type="methods" id="cpt2311-sec-0003">
              <title>METHODS</title>
              <sec id="cpt2311-sec-0004">
                <title>Source of patients, study design, and study population</title>
                <p>The design of the open‐label, randomized phase III trial CCTG MA.27 (ClinicalTrials.gov identifier: NCT00066573), including eligibility criteria, randomization, treatment plan, follow‐up, and monitoring and primary statistical analyses have been described elsewhere.<xref rid="cpt2311-bib-0010" ref-type="bibr"><sup>10</sup></xref> In brief, 7,576 postmenopausal patients with hormone receptor‐positive breast cancer were randomized to anastrozole (1 mg/day) or exemestane (25 mg/day) as adjuvant therapy with planned treatment duration of 5 years. Only North American patients (6,827 of 7,576 of MA.27 accrual) were offered participation in the collection of blood specimens, and 5,221 of the North American patients contributed blood and gave consent for genetic testing. This research was approved by health regulatory authorities and the institutional review boards of participating centers.</p>
                <p>Genotyping was performed in three cohorts as detailed in Supplementary Material.<xref rid="cpt2311-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="cpt2311-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="cpt2311-bib-0017" ref-type="bibr"><sup>17</sup></xref> For the current analysis, we restricted the studies to the White only population that included 4,465 patients with 245 breast events: 2,226 patients on the anastrozole arm with 121 breast events, and 2,239 patients on the exemestane arm with 124 breast events. African American and Han Chinese cohorts had nine breast events in the combined exemestane and anastrozole cohorts. In addition, we did not have breast events in Han Chinese for the exemestane cohort; therefore, the covariate models with all races were unstable and did not converge. Hence, we chose to analyze only the White cohort.</p>
              </sec>
              <sec id="cpt2311-sec-0005">
                <title>Primary end point</title>
                <p>The primary outcome was the STEEP<xref rid="cpt2311-bib-0018" ref-type="bibr"><sup>18</sup></xref> end point of Breast Cancer Free Interval (BCFI), defined as the time from randomization to the first local‐regional breast cancer recurrence (including ipsilateral ductal carcinoma in situ (DCIS)), distant breast cancer recurrence, contralateral breast cancer (invasive or DCIS), or death with or from breast cancer without a prior recurrence date. Follow‐up was censored at non‐breast cancer death or the longest follow‐up without recurrence.</p>
              </sec>
              <sec id="cpt2311-sec-0006">
                <title>Statistical design</title>
                <p>The pharmacogenomic analysis focused on identifying SNPs effects whose associations with BCFI were significantly different based on the treatment (anastrozole or exemestane). Thus, our analysis used a stratified genomewide Cox‐proportional hazards model using an SNP/treatment interaction term and was controlled for significant stratification factors (chemotherapy, nodal status, and trastuzumab), and additional clinical covariates, including treatment arm, cohort, estrogen receptor (ER)/progesterone receptor status, T stage, Eastern Cooperative Oncology Group (ECOG) performance score, and bisphosphonate use. To avoid bias that might arise from differences in genetic ancestry (i.e., population stratification), the EigenStrat software was used to determine eigenvalues for the SNP correlation matrix that statistically differed from zero based on Tracy–Widom <italic toggle="yes">P</italic> values.<xref rid="cpt2311-bib-0019" ref-type="bibr"><sup>19</sup></xref>, <xref rid="cpt2311-bib-0020" ref-type="bibr"><sup>20</sup></xref> All the analyses were run using the R statistical computing package, PLINK,<xref rid="cpt2311-bib-0021" ref-type="bibr"><sup>21</sup></xref> and SAS (SAS Institute, Cary, NC, USA).</p>
              </sec>
              <sec id="cpt2311-sec-0007">
                <title>Reporter gene assay</title>
                <p>Luciferase reporter gene constructs containing rs1877193 wild type (WT) and variant genotypes were generated by gene synthesis. Specifically, a 1,001 bp segment of the <italic toggle="yes">LY75</italic> promoter containing estrogen response element (ERE) and rs1877193 SNP WT or variant genotype was synthesized and cloned into the Kpnl and Xhol sites upstream of the luc2 gene in the pGL4‐Basic vector (Promega, Madison, WI, USA). Reporter gene constructs containing WT or variant SNP genotypes were transfected into cells using Lipofectamine 2000 (Invitrogen, Waltham, MA, USA). A pRL‐CMV vector (Promega) that expresses renilla luciferase was co‐transfected as an internal control. After AI treatment, the cells were lysed, and luciferase activity was determined using the Dual‐Luciferase Reporter assay system (Promega). Renilla luciferase activity was used to correct for transfection efficiency.</p>
              </sec>
              <sec id="cpt2311-sec-0008">
                <title>Statistical analysis</title>
                <p>For cell survival, proliferation, gene expression, CHIP, reporter gene assays, and quantifications, data are represented as the mean ± SEM of three independent experiments. Unless otherwise described, two‐way analysis of variance (ANOVA) was performed to test group difference. Then post hoc analysis was carried out to check if specific groups are significantly different or similar. Tukey Honest Significant Differences (HSD; R function: TukeyHSD), which is essentially a modified <italic toggle="yes">t</italic>‐test corrected for multiple comparisons, was applied in this analysis. Statistical significance level is 0.05.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="cpt2311-sec-0009">
              <title>RESULTS</title>
              <sec id="cpt2311-sec-0010">
                <title>Genetic variation interaction with aromatase inhibitor therapy</title>
                <p>The Participant Flow Diagram for the MA.27 trial (<bold>Figure </bold>
<xref rid="cpt2311-sup-0001" ref-type="supplementary-material"><bold>S1</bold></xref>) shows the patients included in the SNP‐treatment interaction studies. The analysis cohort was restricted to 4,465 White patients (2,226 patients treated with anastrozole and 2,239 patients treated with exemestane, with 121 and 124 breast events in each arm). To determine the possible SNP‐treatment interaction effect using the MA.27 cohort, we performed a stratified Cox‐proportional hazard analysis utilizing stratification factors and other covariates as detailed in the Methods section. The Manhattan plot (<bold>Figure </bold>
<xref rid="cpt2311-fig-0001" ref-type="fig"><bold>1a</bold></xref>) shows the results of SNP‐treatment interaction analyses for BCFI, and the quantile‐quantile plot (<bold>Figure </bold>
<xref rid="cpt2311-sup-0001" ref-type="supplementary-material"><bold>S2</bold></xref>
<bold>A</bold>) revealed a lambda of 1.025. Although none of these SNPs met the criteria for genomewide significance, we had used the largest sample set available to perform the GWAS, so we chose to pursue the results functionally and mechanistically. The results of those studies supported the novel insights that are described subsequently regarding genetic mechanisms for variation in AI effect.</p>
                <fig position="float" fig-type="Figure" id="cpt2311-fig-0001">
                  <label>Figure 1</label>
                  <caption>
                    <p>SNP treatment interaction analysis. (<bold>a</bold>) SNP‐treatment interaction GWAS Manhattan Plot. (<bold>b</bold>) Anastrozole arm GWAS Manhattan Plot. (<bold>c</bold>) Exemestane arm GWAS Manhattan Plot. (<bold>d</bold>) SNP‐treatment interaction GWAS signals show opposite effects on BCFI in the anastrozole arm GWAS vs. the exemestane arm GWAS. Hazard ration from two GWASs. X axis: Hazard ration from the exemestane arm GWAS (BCFI_EXE_HR). Y axis: Hazard ration from the anastrozole arm GWAS (BCFI_ANA_HR). Significance indicated by size, and averaged log (p value) by color. (<bold>e</bold>) 261 SNP‐treatment interaction GWAS signals showed opposite effects on BCFI in the anastrozole arm GWAS (green) vs. the exemestane arm GWAS (blue), but not associated with BCFI in the combined cohort GWAS (red). Three sets of ordered HRs of 261 SNPs from three GWASs; the whole cohort (red), patients who received only anastrozole (green) and patients who received only exemestane (blue). (<bold>f</bold>) Venn diagram of the SNPs that were selected after performing clumping using three different criteria (see Methods). BCFI, Breast Cancer Free Interval; GWAS, genomewide association studies; HR, hazard ratio; MAF, Minor Allele Frequency; SNP, single‐nucleotide polymorphism.</p>
                  </caption>
                  <graphic xlink:href="CPT-110-1038-g001" position="anchor" id="jats-graphic-1"/>
                </fig>
                <p><bold>Table </bold><xref rid="cpt2311-sup-0002" ref-type="supplementary-material"><bold>S1</bold></xref> presents the 887 significant SNP‐by‐drug interactions (<italic toggle="yes">P</italic> &lt; 1.0E‐04) on BCFI when comparing exemestane to anastrozole. Signals with an Exemestane/Anastrozole hazard ratio (HR) of &gt; 1 indicate that patients carrying a variant SNP genotype have reduced efficacy when treated with exemestane compared with anastrozole. On the contrary, signals with an Exemestane/Anastrozole HR of &lt; 1, indicate that patients carrying a variant SNP genotype have a better outcome when treated with exemestane compared with anastrozole. We next investigated these 887 SNPs for their associations with anastrozole (<bold>Figure </bold>
<xref rid="cpt2311-fig-0001" ref-type="fig"><bold>1b</bold></xref>, <bold>Figure </bold>
<xref rid="cpt2311-sup-0001" ref-type="supplementary-material"><bold>S2</bold></xref>
<bold>B</bold>) and exemestane (<bold>Figure </bold>
<xref rid="cpt2311-fig-0001" ref-type="fig"><bold>1c</bold></xref>, <bold>Figure </bold>
<xref rid="cpt2311-sup-0001" ref-type="supplementary-material"><bold>S2</bold></xref>
<bold>C</bold>) efficacy (BCFI) separately based on GWAS conducted within each treatment arm in the MA.27 study. One hundred thirty‐four of 887 SNPs (<bold>Figure </bold>
<xref rid="cpt2311-fig-0001" ref-type="fig"><bold>1d</bold></xref>, <bold>Table </bold>
<xref rid="cpt2311-sup-0003" ref-type="supplementary-material"><bold>S2</bold></xref>) were associated with better outcomes (longer BCFI) in exemestane‐treated patients (HR = 0.04~0.71, <italic toggle="yes">P</italic> = 2.21E‐04~0.009), but with shorter BCFI in anastrozole‐treated patients (HR = 1.42~3.43, <italic toggle="yes">P</italic> = 6.36E‐05~0.0097). One hundred twenty‐seven of 887 SNPs (<bold>Figure </bold>
<xref rid="cpt2311-fig-0001" ref-type="fig"><bold>1d</bold></xref>, <bold>Table </bold>
<xref rid="cpt2311-sup-0003" ref-type="supplementary-material"><bold>S2</bold></xref>) were associated with shorter BCFI in exemestane‐treated patients (HR=1.41~2.94, <italic toggle="yes">P</italic> = 2.21E‐04~0.0099), but with longer BCFI in anastrozole‐treated patients (HR = 0.01~0.68, <italic toggle="yes">P</italic> = 1.99E‐05~0.0095). However, these two groups of SNPs (134 + 127 = 261 SNPs; <bold>Figure </bold>
<xref rid="cpt2311-fig-0001" ref-type="fig"><bold>1e</bold></xref>, <bold>Figure </bold>
<xref rid="cpt2311-sup-0001" ref-type="supplementary-material"><bold>S3</bold></xref>
<bold>A</bold>) showed no association with BCFI in the combined analysis of anastrozole and exemestane (HR = 0.90~1.56, <italic toggle="yes">P</italic> = 0.08~0.99) based on our previous published GWAS results for the MA.27 trial.<xref rid="cpt2311-bib-0014" ref-type="bibr"><sup>14</sup></xref>
<bold>Figure </bold>
<xref rid="cpt2311-fig-0001" ref-type="fig"><bold>1e</bold></xref> plots 3 sets of ordered HRs of 261 SNPs from 3 GWASs; the whole cohort (red), patients who received anastrozole (green), and patients who received exemestane (blue). In the left half of the plot, SNPs whose HRs range from 0 to 1 in exemestane cohort have an HR ranging from 1 to 3 in the anastrozole cohort implying the presence of minor alleles in these SNPs will be protective if treated with exemestane as compared to anastrozole. Similarly, in the right half of the plot, we see a set of SNPs whose HRs suggest being protective alleles for anastrozole and risk alleles for exemestane. HRs obtained from the whole cohort remained constant around one, suggesting low power to detect any SNP effect. In summary, the current analyses revealed a difference in anastrozole and exemestane efficacy in the context of the host genome and identified germline genetic variants that might be able to identify which AI might be superior in preventing breast cancer recurrence in that specific patient. Importantly, over 98.7% of the signals (876 of 887 SNPs) were lost (<italic toggle="yes">P</italic> &gt; 0.01) in the GWAS analysis when anastrozole and exemestane were combined. Moreover, 261 SNPs were observed to be risk alleles for one AI and protective for the other (<bold>Figure </bold>
<xref rid="cpt2311-fig-0001" ref-type="fig"><bold>1e</bold></xref>).</p>
              </sec>
              <sec id="cpt2311-sec-0011">
                <title>Genetic model for guiding aromatase inhibitor selection</title>
                <p>We next set out to build a genetic model for guiding AI selection. Of the 261 SNPs, 105 SNPs marginally affected BCFI based on any of the clinical covariates and were removed from further analysis. After filtering the 105 SNPs, the remaining 156 SNPs underwent linkage disequilibrium (LD) –clumping analyses.<xref rid="cpt2311-bib-0022" ref-type="bibr"><sup>22</sup></xref> In brief, “clumping” reported the SNPs that were within 500 kb of the significant SNP, were in high LD (<italic toggle="yes">r</italic>
<sup>2</sup> &gt; 0.8), and had a low <italic toggle="yes">P</italic> value. For anastrozole and exemestane cohorts, we chose a <italic toggle="yes">P</italic> value cutoff &lt; 0. 001, and for the interaction GWAS analysis, we chose a <italic toggle="yes">P</italic> value cutoff &lt; 9.99E‐05. From the clumping analysis for each study, we obtained a set of SNPs that were common and unique to each study, as shown in <bold>Figure </bold>
<xref rid="cpt2311-fig-0001" ref-type="fig"><bold>1f</bold></xref> and <bold>Table </bold>
<xref rid="cpt2311-tbl-0001" ref-type="table"><bold>1</bold></xref>. Coincidentally, the number of SNPs remaining after clumping was 46 for all 3 studies. As shown in the Venn diagram, we overlapped the SNP IDs from the three studies after clumping to identify a reduced list of SNPs that were significantly associated with anastrozole and with exemestane. Thirty‐two SNPs were retained after clumping in all the 3 studies, 14 of those SNPs were present in 2 or more studies (interaction and anastrozole or interaction and exemestane LD analysis), 8 SNPs were unique to exemestane only, and 6 SNPs were retained in the anastrozole only clumping analysis, as shown in <bold>Table </bold>
<xref rid="cpt2311-sup-0001" ref-type="supplementary-material"><bold>S3</bold></xref>. We ultimately obtained a list of 60 unique SNPs (32 + 14 + 8 + 6 = 60) as our SNP panel. Note that these SNPs had been obtained from a pure discovery activity and had not been tested or validated in an independent set. <bold>Figure </bold>
<xref rid="cpt2311-sup-0001" ref-type="supplementary-material"><bold>S3</bold></xref>
<bold>b,c</bold> show the HR for SNPs selected based on each of the drug‐specific association results.</p>
                <table-wrap position="float" id="cpt2311-tbl-0001" content-type="Table">
                  <label>Table 1</label>
                  <caption>
                    <p>SNPs that remained significant after clumping in each of the three GWAS</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">GWAS used</th>
                        <th align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value cutoff</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">No. of SNPs from clumping</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">BCFI Interaction</td>
                        <td align="center" rowspan="1" colspan="1">9.99E‐05</td>
                        <td align="center" rowspan="1" colspan="1">46</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">BCFI with anastrozole cohort</td>
                        <td align="center" rowspan="1" colspan="1">0.001</td>
                        <td align="center" rowspan="1" colspan="1">46</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">BCFI with exemestane cohort</td>
                        <td align="center" rowspan="1" colspan="1">0.001</td>
                        <td align="center" rowspan="1" colspan="1">46</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="cpt2311-ntgp-0001">
                    <fn id="cpt2311-note-0002">
                      <p>BCFI, Breast Cancer Free Interval; GWAS, genomewide association studies; SNP, single‐nucleotide polymorphism.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
              </sec>
              <sec id="cpt2311-sec-0012">
                <title>Functional genomics of the top treatment interacting GWAS SNPs</title>
                <p>The next series of experiments were performed to determine the function of the 261 SNPs from our SNP‐treatment interaction analysis. Expression quantitative trait loci (eQTL) are particularly useful for annotating variants associated with complex traits.<xref rid="cpt2311-bib-0023" ref-type="bibr"><sup>23</sup></xref> We, therefore, determined whether any of the 261 SNPs were eQTL SNPs using the Genotype‐Tissue Expression (GTEx) website.<xref rid="cpt2311-bib-0024" ref-type="bibr"><sup>24</sup></xref> Cis‐eQTL analysis identified 46 SNPs that were eQTLs with 2 genes in breast tissue, and an additional 4 genes in other tissues (<bold>Table </bold>
<xref rid="cpt2311-sup-0001" ref-type="supplementary-material"><bold>S4</bold></xref>). Collectively, the eQTL analysis identified six “eGenes” (genes exhibiting association with genotypes for at least one SNP). The SNPs associated with any given gene were in high LD with each other, with pairwise correlation <italic toggle="yes">r</italic>
<sup>2</sup> = 1.</p>
                <p>We then investigated which SNP‐eGenes were differentially associated with efficacy for anastrozole and exemestane. We took advantage of cell lines selected on the basis of each of the 6 eQTL SNP genotypes from a genomic data‐rich panel of 300 human lymphoblastoid cell lines (LCLs) that has proven to be a powerful tool for testing pharmacogenomic hypotheses.<xref rid="cpt2311-bib-0015" ref-type="bibr"><sup>15</sup></xref>, <xref rid="cpt2311-bib-0025" ref-type="bibr"><sup>25</sup></xref>, <xref rid="cpt2311-bib-0026" ref-type="bibr"><sup>26</sup></xref>, <xref rid="cpt2311-bib-0027" ref-type="bibr"><sup>27</sup></xref>, <xref rid="cpt2311-bib-0028" ref-type="bibr"><sup>28</sup></xref>, <xref rid="cpt2311-bib-0029" ref-type="bibr"><sup>29</sup></xref> We selected four LCLs with homozygous WT genotypes for each SNP and four LCLs with the variant genotypes with detectable aromatase expression (<bold>Figure </bold>
<xref rid="cpt2311-sup-0001" ref-type="supplementary-material"><bold>S4</bold></xref>
<bold>a</bold>) to test the impact of anastrozole and exemestane on cell growth. We ensured that the aromatase activity was inhibited by anastrozole and exemestane (<bold>Figure </bold>
<xref rid="cpt2311-sup-0001" ref-type="supplementary-material"><bold>S4</bold></xref>
<bold>b</bold>). The eQTL SNPs for the following genes, <italic toggle="yes">LY75</italic>, <italic toggle="yes">GPR160</italic>, <italic toggle="yes">PLA2R1</italic>, <italic toggle="yes">NPLOC4</italic>, and <italic toggle="yes">NT5C3A</italic>, showed that the variant genotypes all had a differential effect on cell growth between exemestane and anastrozole (<bold>Figure </bold>
<xref rid="cpt2311-fig-0002" ref-type="fig"><bold>2a</bold></xref>, <bold>Figure </bold>
<xref rid="cpt2311-sup-0001" ref-type="supplementary-material"><bold>S4</bold></xref>
<bold>c</bold>). Among these five eQTL relationships, three were not consistent with our analysis results. The directional effect of the eQTL SNPs for <italic toggle="yes">NT5C3A</italic> on individual drug efficacy identified through SNP‐drug interaction GWAS was not consistent with experimental results (<bold>Figure </bold>
<xref rid="cpt2311-sup-0001" ref-type="supplementary-material"><bold>S4</bold></xref>, <bold>Table </bold>
<xref rid="cpt2311-sup-0002" ref-type="supplementary-material"><bold>S1</bold></xref>). As for the <italic toggle="yes">NPLOC4</italic> SNPs, anastrozole, in comparison to exemestane, had greater growth inhibition on cells with variant SNP genotypes, which was consistent with the SNP‐drug interaction GWAS results (Minor Allele Frequency (MAF) = 0.037, HR: Anas vs. Exem = 0). However, the anastrozole to exemestane HR was 0 due to the low MAF, resulting in low statistical power,<xref rid="cpt2311-bib-0030" ref-type="bibr"><sup>30</sup></xref>, <xref rid="cpt2311-bib-0031" ref-type="bibr"><sup>31</sup></xref> raising the possibility that the association might be a false positive. Indeed, regardless of the <italic toggle="yes">NPLOC4</italic> SNP genotype, cells grew faster in the presence of exemestane compared with anastrozole (<bold>Figure </bold>
<xref rid="cpt2311-sup-0001" ref-type="supplementary-material"><bold>S4</bold></xref>). The eQTL SNPs for <italic toggle="yes">LY75</italic> (lymphocyte antigen 75), <italic toggle="yes">GPR160</italic> (G Protein‐Coupled Receptor 160), and <italic toggle="yes">PLA2R1</italic> (Phospholipase A2 Receptor 1) showed a consistent effect on drug response between GWAS result and the experimental validation (<bold>Figure </bold>
<xref rid="cpt2311-sup-0001" ref-type="supplementary-material"><bold>S4</bold></xref>, <bold>Figure </bold>
<xref rid="cpt2311-fig-0002" ref-type="fig"><bold>2a</bold></xref>, <bold>Table </bold>
<xref rid="cpt2311-sup-0002" ref-type="supplementary-material"><bold>S1</bold></xref>), suggesting that these SNPs may differentially affect anastrozole and exemestane response through regulation of the <italic toggle="yes">LY75</italic>, <italic toggle="yes">GPR160</italic>, and <italic toggle="yes">PLA2R1</italic> genes. We sought to study the functional impact of <italic toggle="yes">LY75</italic>, <italic toggle="yes">GPR160</italic>, and <italic toggle="yes">PLA2R1</italic> genes, which are expressed in breast tissue (<bold>Figure </bold>
<xref rid="cpt2311-sup-0001" ref-type="supplementary-material"><bold>S5</bold></xref>). Knockdown of <italic toggle="yes">LY75</italic> and <italic toggle="yes">GPR160</italic>, but not <italic toggle="yes">PLA2R1</italic>, decreased breast cancer cell proliferation (<bold>Figure </bold>
<xref rid="cpt2311-fig-0002" ref-type="fig"><bold>2b,c</bold></xref>, <bold>Figure </bold>
<xref rid="cpt2311-sup-0001" ref-type="supplementary-material"><bold>S6</bold></xref>
<bold>a</bold>). We then validated the interaction effects of these three genes with AIs. <italic toggle="yes">LY75</italic> and <italic toggle="yes">GPR160</italic>, but not <italic toggle="yes">PLA2R1</italic>, knockdown cells grew more slowly in the presence of anastrozole compared to exemestane (<bold>Figure </bold>
<xref rid="cpt2311-fig-0002" ref-type="fig"><bold>2d,e</bold></xref>, <bold>Figure </bold>
<xref rid="cpt2311-sup-0001" ref-type="supplementary-material"><bold>S6</bold></xref>
<bold>b</bold>). Therefore, we chose to focus on the functional implications of the <italic toggle="yes">LY75</italic> and <italic toggle="yes">GPR160</italic> SNPs because those SNPs may represent regulatory variants.</p>
                <fig position="float" fig-type="Figure" id="cpt2311-fig-0002">
                  <label>Figure 2</label>
                  <caption>
                    <p><italic toggle="yes">LY75</italic> and <italic toggle="yes">GPR160</italic> SNPs dependent effect on cell proliferation. (<bold>a</bold>) Cell growth of LCLs with known genotypes for variant (V) and wild type (WT) <italic toggle="yes">LY75</italic> SNPs and <italic toggle="yes">GPR160</italic> SNP were incubated with 100 nM anastrozole (Ana) or exemestane (Exe) for the indicated times. WT: homozygous WT, V: heterozygous and v/v: homozygous variant LCLs (<italic toggle="yes">n</italic> = 3, means ± SEM). (<bold>b</bold>) Cell growth of MCF‐7 and T47D cells after knocking down <italic toggle="yes">LY75</italic>. (<bold>c</bold>) Cell growth of MCF‐7 and T47D cells after knocking down <italic toggle="yes">GPR160</italic> (<italic toggle="yes">n</italic> = 3, means ± SEM). **<italic toggle="yes">P</italic> &lt; 0.01. Statistical test: two‐way ANOVA. (<bold>d</bold>) MCF‐7 and T47D cells were transfected with <italic toggle="yes">LY75</italic> siRNA, 24 hours later cells were treated with Ana or Exe. Cell growth of MCF‐7 and T47D cells were then measured (<italic toggle="yes">n</italic> = 3, means ± SEM). **<italic toggle="yes">P</italic> &lt; 0.01. (<bold>e</bold>) MCF‐7 and T47D cells were transfected with <italic toggle="yes">GPR160</italic> siRNA, 24 hours later cells were treated with Ana or Exe. Cell growth of MCF‐7 and T47D cells were then measured (<italic toggle="yes">n</italic> = 3, means ± SEM). **<italic toggle="yes">P</italic> &lt; 0.01. Statistical test: two‐way ANOVA. (<bold>f</bold>) The rs1877193 SNP and the rs62293499 SNP cis‐eQTLs for <italic toggle="yes">LY75</italic> and <italic toggle="yes">GPR160</italic>, respectively in GTEX. ANOVA, analysis of variance; eQTL, expression quantitative trait loci; LCL, lymphoblastoid cell line; SNP, single‐nucleotide polymorphism.</p>
                  </caption>
                  <graphic xlink:href="CPT-110-1038-g004" position="anchor" id="jats-graphic-3"/>
                </fig>
              </sec>
              <sec id="cpt2311-sec-0013">
                <title>Associations with breast cancer free interval in treatment‐stratified analysis</title>
                <p>The two common SNPs (MAF = 0.455), rs1877193 and rs6735923, were eQTLs for <italic toggle="yes">LY75</italic> gene expression in breast tissue (<bold>Figure </bold>
<xref rid="cpt2311-fig-0002" ref-type="fig"><bold>2f</bold></xref>), and they were also in perfect LD (<italic toggle="yes">r</italic>
<sup>2</sup> = 1). These 2 SNPs mapped upstream of <italic toggle="yes">LY75</italic> on chromosome 2 (<bold>Figure </bold>
<xref rid="cpt2311-fig-0003" ref-type="fig"><bold>3a,b</bold></xref>) and had significant interaction with treatments (SNP rs1877193: HR: Exe/Ana = 0.45; SNP rs6735923: HR: Exe/Ana = 0.46; <bold>Table </bold>
<xref rid="cpt2311-sup-0004" ref-type="supplementary-material"><bold>S5</bold></xref>), indicating ~ 55% reduction in the hazard for a breast cancer event for patients carrying the variant genotype treated with exemestane compared with anastrozole. In treatment‐specific cohort GWAS analysis, the two SNPs were associated with opposite effects on risk for a breast event between the two treatment cohorts: increased risk in the anastrozole cohort (HR = 1.57, 1.58; <italic toggle="yes">P</italic> = 5.3E‐04, 6.9E‐04), and decreased risk in the exemestane cohort (HR = 0.70, 0.71; <italic toggle="yes">P</italic> = 6.0E‐03, 8.0E‐03). However, the two SNPs showed no association with breast events if the two treatment arms were combined<xref rid="cpt2311-bib-0014" ref-type="bibr"><sup>14</sup></xref> (HR = 1.07, 1.08; <italic toggle="yes">P</italic> = 0.37, 0.40; <bold>Table </bold>
<xref rid="cpt2311-sup-0004" ref-type="supplementary-material"><bold>S5</bold></xref>).</p>
                <fig position="float" fig-type="Figure" id="cpt2311-fig-0003">
                  <label>Figure 3</label>
                  <caption>
                    <p><italic toggle="yes">LY75</italic> SNP‐ and anastrozole‐dependent gene regulation. (<bold>a, b</bold>) Locus zoom plot of the chromosome 2 region surrounding the <italic toggle="yes">LY75</italic> gene. (<bold>c, d</bold>) SNP‐androstenedione‐ and anastrozole (<bold>c</bold>, Ana) or exemestane (<bold>d</bold>, Exe) ‐dependent regulation of LY75 gene expression in LCLs selected based on <italic toggle="yes">LY75</italic> SNP genotypes. WT: homozygous WT, V: heterozygous variant LCLs. (<italic toggle="yes">n</italic> = 3, means ± SEM). **<italic toggle="yes">P</italic> &lt; 0.01. (<bold>e</bold>) Schematic figure showing the estrogen response elements (ERE) surrounding the rs1877193 SNP. (<bold>f</bold>) ERα ChIP assay showing SNP dependent ERα binding to the ERE region that is 200 bp upstream from the rs1877193 SNP in LCLs with different genotypes treated with the indicated drugs: androstenedione (A), anastrozole (Ana), and exemestane (Exe) (<italic toggle="yes">n</italic> = 3, means ± SEM). **<italic toggle="yes">P</italic> &lt; 0.01. Statistical test: two‐way ANOVA. (<bold>g</bold>) MCF‐7 and T47D cells were transfected with ESR1 siRNA. Forty‐eight hours later, mRNA was harvested for qRT‐PCR (<italic toggle="yes">n</italic> = 3, means ± SEM). **<italic toggle="yes">P</italic> &lt; 0.01. (<bold>h–j</bold>) Reporter gene assays for the <italic toggle="yes">LY75</italic> rs1877193 SNP. The rs1877193 SNP was included in the <italic toggle="yes">LY75</italic> promotor sequence that was subcloned upstream of the luciferase reporter gene, Luc2. The plasmids contained either WT or variant sequences for the SNP and were transfected into <bold>h</bold> LCLs, <bold>i</bold> MCF‐7, and <bold>j</bold> T47D cells. Values shown for <bold>h–j</bold> are ratios of relative light units (RLUs) compared with the internal reference after vehicle (baseline), A, Ana, or Exe treatment (<italic toggle="yes">n</italic> = 3, means ± SEM). **<italic toggle="yes">P</italic> &lt; 0.01, ns, not significant. Statistical test: two‐way ANOVA. ANOVA, analysis of variance; LCL, lymphoblastoid cell line; PCR, polymerase chain reaction; qRT‐PCR, quantitative real‐time polymerase chain reaction; SNP, single‐nucleotide polymorphism.</p>
                  </caption>
                  <graphic xlink:href="CPT-110-1038-g005" position="anchor" id="jats-graphic-5"/>
                </fig>
                <p>The <italic toggle="yes">GPR160</italic> SNP rs62293499 mapped downstream of <italic toggle="yes">GPR160</italic> on chromosome 3p7, and the variant allele was associated with increased <italic toggle="yes">GPR160</italic> expression (<bold>Figure </bold>
<xref rid="cpt2311-fig-0002" ref-type="fig"><bold>2f</bold></xref>). The minor allele (MAF = 0.338) was associated with decreased risk for breast events when treated with exemestane compared with anastrozole (HR: Exe/Ana = 0.43; <bold>Table </bold>
<xref rid="cpt2311-sup-0004" ref-type="supplementary-material"><bold>S5</bold></xref>). This effect was also confirmed by independent GWAS analysis in each treatment arm, in that a trend for increased risk of a breast event within the anastrozole arm (HR = 1.39, <italic toggle="yes">P</italic> = 0.014), and for significantly decreased risk within the exemestane arm (HR = 0.58, <italic toggle="yes">P</italic> = 2.0E‐04) were observed (<bold>Table </bold>
<xref rid="cpt2311-sup-0004" ref-type="supplementary-material"><bold>S5</bold></xref>). Similar to the <italic toggle="yes">LY75</italic> SNPs, rs62293499 was not associated with breast events when the two treatment arms were combined (HR = 0.92, <italic toggle="yes">P</italic> = 0.39; <bold>Table </bold>
<xref rid="cpt2311-sup-0004" ref-type="supplementary-material"><bold>S5</bold></xref>).</p>
              </sec>
              <sec id="cpt2311-sec-0014">
                <title>LY75 SNP effects differ in the presence of anastrozole vs. exemestane</title>
                <p>We next set out to determine whether and how the <italic toggle="yes">LY75</italic> SNPs might have a differential impact on response to the two AIs through <italic toggle="yes">LY75</italic>. We selected LCLs with WT and variant genotypes for <italic toggle="yes">LY75</italic> SNPs, and then exposed them to an AI in the presence of androstenedione, a precursor of estrogen. The variant cell lines showed a reduction of <italic toggle="yes">LY75</italic> expression in response to androstenedione exposure, whereas WT LCLs did not (<bold>Figure </bold>
<xref rid="cpt2311-fig-0003" ref-type="fig"><bold>3c,d</bold></xref>). Addition of anastrozole showed a striking reversal of the <italic toggle="yes">LY75</italic> expression pattern in LCLs with variant SNP genotypes: <italic toggle="yes">LY75</italic> expression increased almost threefold with the addition of anastrozole. In contrast, WT expression did not change (<bold>Figure </bold>
<xref rid="cpt2311-fig-0003" ref-type="fig"><bold>3c</bold></xref>). Of importance, exemestane did not change the expression patterns of <italic toggle="yes">LY75</italic> in either WT or variant genotype LCLs (<bold>Figure </bold>
<xref rid="cpt2311-fig-0003" ref-type="fig"><bold>3d</bold></xref>).</p>
              </sec>
              <sec id="cpt2311-sec-0015">
                <title>Anastrozole, but not exemestane, regulates LY75 SNP‐dependent ERα/ERE binding</title>
                <p>To determine whether the SNP‐ and AI‐dependent <italic toggle="yes">LY75</italic> gene regulation was mediated by ERα, we first identified two EREs; 2 bp overlap with each other) located ~ 200 bp distant from the <italic toggle="yes">LY75</italic> SNP rs1877193 based on ENCODE data (<bold>Figure </bold>
<xref rid="cpt2311-fig-0003" ref-type="fig"><bold>3e</bold></xref>). We then performed ChIP assays with ERα antibody and found that the rs1877193 SNP (<bold>Figure </bold>
<xref rid="cpt2311-fig-0003" ref-type="fig"><bold>3f</bold></xref>) showed striking differential binding to the ERE that was located closest to the SNP, with greater binding for the variant SNP genotype in the presence of androstenedione, but less binding when additional anastrozole was present. However, this differential binding pattern was not detected after exemestane treatment (<bold>Figure </bold>
<xref rid="cpt2311-fig-0003" ref-type="fig"><bold>3f</bold></xref>). <italic toggle="yes">LY75</italic> expression was reduced whereas ERα/ERE binding increased in cells with the variant genotypes in response to androstenedione exposure, suggesting that ERα functions as a transcription repressor of <italic toggle="yes">LY75</italic>. Indeed, <italic toggle="yes">LY75</italic> expression increased when ESR1 was knocked down (<bold>Figure </bold>
<xref rid="cpt2311-fig-0003" ref-type="fig"><bold>3g</bold></xref>). These results were compatible with our SNP‐treatment interaction analysis results in that variant <italic toggle="yes">LY75</italic> SNP genotypes could differentiate anastrozole from exemestane in the risk for a breast event during 5 years of AI therapy for those enrolled in MA.27.</p>
                <p>Finally, to determine whether the differences in binding shown in <bold>Figure </bold>
<xref rid="cpt2311-fig-0003" ref-type="fig"><bold>3f</bold></xref> might have functional consequences; we created reporter gene constructs that included ~ 1.1 kb of the <italic toggle="yes">LY75</italic> promoter with WT and variant genotypes for the rs1877193 SNP. These reporter gene constructs were then transfected into different cell lines to compare <italic toggle="yes">LY75</italic> transcriptional activities for WT and variant SNP genotypes in those cells. within the presence of androstenedione, cells transfected with the variant construct showed higher <italic toggle="yes">LY75</italic> transcriptional activity than did cells transfected with the WT construct. However, when the cells were incubated with the addition of 100 nM anastrozole, the transcriptional activity in cells transfected with the variant SNP construct decreased (<bold>Figure </bold>
<xref rid="cpt2311-fig-0003" ref-type="fig"><bold>3h–j</bold></xref>). We did not observe any change when we repeated the same experiments with exemestane (<bold>Figure </bold>
<xref rid="cpt2311-fig-0003" ref-type="fig"><bold>3h–j</bold></xref>).</p>
              </sec>
              <sec id="cpt2311-sec-0016">
                <title>LY75 suppression directs breast cancer epithelial‐to‐mesenchymal transition</title>
                <p>To identify molecular mechanisms relevant to the <italic toggle="yes">LY75</italic>—treatment interaction, we interrogated The Cancer Genome Atlas (TCGA)<xref rid="cpt2311-bib-0032" ref-type="bibr"><sup>32</sup></xref> for genes co‐expressed with <italic toggle="yes">LY75</italic> in ER+ breast cancer sample set<xref rid="cpt2311-bib-0033" ref-type="bibr"><sup>33</sup></xref> using the cBioPortal online platform. After filtering the co‐expression gene prediction results, 2,352 predicted genes (<bold>Figure </bold>
<xref rid="cpt2311-fig-0004" ref-type="fig"><bold>4a</bold></xref>) with Spearman’s correlations ≥ 0.3 or ≤ −0.3 were selected (<bold>Table </bold>
<xref rid="cpt2311-sup-0001" ref-type="supplementary-material"><bold>S6</bold></xref>). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of these 2,352 genes identified PI3K‐AKT, MAPK, cell adhesion, and JAK‐STAT pathways (<bold>Figure </bold>
<xref rid="cpt2311-fig-0004" ref-type="fig"><bold>4b</bold></xref>). We evaluated the top pathways, and our results revealed that JAK/STAT signaling was dysregulated by <italic toggle="yes">LY75</italic> depletion (<bold>Figure </bold>
<xref rid="cpt2311-fig-0004" ref-type="fig"><bold>4c</bold></xref>). Activation of the JAK/STAT3 signaling via IL‐6/IL‐6R leads to increased metastasis resulting from enhanced epithelial‐to‐mesenchymal (EMT).<xref rid="cpt2311-bib-0034" ref-type="bibr"><sup>34</sup></xref>, <xref rid="cpt2311-bib-0035" ref-type="bibr"><sup>35</sup></xref>, <xref rid="cpt2311-bib-0036" ref-type="bibr"><sup>36</sup></xref>, <xref rid="cpt2311-bib-0037" ref-type="bibr"><sup>37</sup></xref> Remarkably, LY75 suppression induced EMT as shown by the expression of specific EMT markers: a significant decrease of E‐cadherin and EPCAM; an increase of N‐cadherin and SNAIL1 (<bold>Figure </bold>
<xref rid="cpt2311-fig-0004" ref-type="fig"><bold>4c</bold></xref>). <italic toggle="yes">LY75</italic> knockdown cells also displayed decreased proliferation rates compared with the control (<bold>Figure </bold>
<xref rid="cpt2311-fig-0002" ref-type="fig"><bold>2b</bold></xref>), which was associated with decreased AKT and MAPK phosphorylation (<bold>Figure </bold>
<xref rid="cpt2311-fig-0004" ref-type="fig"><bold>4c</bold></xref>). Moreover, <italic toggle="yes">LY75</italic> suppression significantly promoted cell migration (<bold>Figure </bold>
<xref rid="cpt2311-fig-0004" ref-type="fig"><bold>4d</bold></xref>). Thus, the <italic toggle="yes">in vitro</italic> invasiveness and motility of <italic toggle="yes">LY75</italic>‐knockdown cells was inversely correlated with their proliferative potential which might be due to the acquiring of the mesenchymal phenotype.<xref rid="cpt2311-bib-0038" ref-type="bibr"><sup>38</sup></xref> To provide potential clues to the observed genetic correlations, we examined the SNP‐treatment interaction effect on the JAK/STAT and MAPK activities in LCLs with WT and variant genotypes for the <italic toggle="yes">LY75</italic> SNPs. The variant cells showed increased expression of pSTAT3 and decreased pERK in response to androstenedione treatment. In contrast, in WT LCLs, pSTAT3, and pERK, expressions were virtually unchanged with androstenedione. Importantly, the addition of anastrozole, but not exemestane, significantly reduced the pSTAT3 and pERK levels in variant cells (<bold>Figure </bold>
<xref rid="cpt2311-fig-0004" ref-type="fig"><bold>4e</bold></xref>). The next question that we addressed was the possible mechanism by which the <italic toggle="yes">GPR160</italic> SNP might result in differential effects in response to anastrozole and exemestane treatment.</p>
                <fig position="float" fig-type="Figure" id="cpt2311-fig-0004">
                  <label>Figure 4</label>
                  <caption>
                    <p>LY75 suppression directs epithelial‐to‐mesenchymal transition (EMT). (<bold>a</bold>) <italic toggle="yes">LY75</italic> correlated genes in 593 TCGA ER+ patients. (<bold>b</bold>) Pathway analysis of <italic toggle="yes">LY75</italic> correlated gene in TCGA ER+ population. (<bold>c</bold>) Western blot analysis of the expression of different EMT (epithelial and mesenchymal) markers in the control and the <italic toggle="yes">LY75</italic> knockdown breast cancer cells. (<bold>d</bold>) Cell migration of <italic toggle="yes">LY75</italic> knockdown cells was compared to the control cells (Neg). Equal numbers of cells from Neg and siLY75 groups were seeded into 12‐well plates for wound healing assay. Original magnification: ×10. (<bold>e</bold>) <italic toggle="yes">LY75</italic> SNP effect on pSTAT3 and pERK protein levels in LCLs with either WT or variant sequences for the SNP treated with androstenedione (A), anastrozole (Ana), and exemestane (Exe). ER, estrogen receptor; LCL, lymphoblastoid cell line; SNP, single‐nucleotide polymorphism; TCGA, The Cancer Genome Atlas; V, variant; WT, wild type. [Colour figure can be viewed at <ext-link xlink:href="http://wileyonlinelibrary.com" ext-link-type="uri">wileyonlinelibrary.com</ext-link>]</p>
                  </caption>
                  <graphic xlink:href="CPT-110-1038-g003" position="anchor" id="jats-graphic-7"/>
                </fig>
              </sec>
              <sec id="cpt2311-sec-0017">
                <title>Anastrozole differs from exemestane regarding GPR160 SNP‐dependent gene regulation</title>
                <p>The <italic toggle="yes">GPR160</italic> SNP rs62293499 (<bold>Figure </bold>
<xref rid="cpt2311-fig-0005" ref-type="fig"><bold>5a</bold></xref>) variant allele was associated with longer BCFI after treatment with exemestane as compared to anastrozole (<bold>Table </bold>
<xref rid="cpt2311-sup-0004" ref-type="supplementary-material"><bold>S5</bold></xref>). We began our functional genomic studies of the <italic toggle="yes">GPR160</italic> SNP starting with the question of whether <italic toggle="yes">GPR160</italic> expression might be regulated in an SNP‐treatment‐dependent fashion. <italic toggle="yes">GPR160</italic> mRNA expression was induced by exposure to increasing concentrations of androstenedione in cells with WT genotype, but not in those with the variant SNP genotype (<bold>Figure </bold>
<xref rid="cpt2311-fig-0005" ref-type="fig"><bold>5b</bold></xref>). We observed a striking reversal of expression with anastrozole, but not exemestane, that is, increased expression in the presence of anastrozole in cells with variant <italic toggle="yes">GPR160</italic> SNP genotype, but decreased expression in cells with WT genotype (<bold>Figure </bold>
<xref rid="cpt2311-fig-0005" ref-type="fig"><bold>5b</bold></xref>). Several EREs were located within 500 bp of the <italic toggle="yes">GPR160</italic> SNP (<bold>Figure </bold>
<xref rid="cpt2311-fig-0005" ref-type="fig"><bold>5c</bold></xref>), and the rs62293499 SNP genotype was associated with striking differential binding to the EREs, with more binding for the WT SNP genotype in the presence of androstenedione, but a greater binding for the variant SNP when anastrozole was present. Exemestane, however, did not change the binding activity (<bold>Figure </bold>
<xref rid="cpt2311-fig-0005" ref-type="fig"><bold>5d</bold></xref>).</p>
                <fig position="float" fig-type="Figure" id="cpt2311-fig-0005">
                  <label>Figure 5</label>
                  <caption>
                    <p><italic toggle="yes">GPR160</italic> SNP‐ and anastrozole‐dependent gene regulation. (<bold>a</bold>) Locus zoom plot of the chromosome 3 region surrounding the <italic toggle="yes">GPR160</italic> gene. (<bold>b</bold>) SNP‐androstenedione‐ and anastrozole‐dependent regulation of <italic toggle="yes">GPR160</italic> gene expression in LCLs selected based on the <italic toggle="yes">GPR160</italic> SNP genotypes. WT: homozygous WT, V: homozygous variant LCLs (<italic toggle="yes">n</italic> = 3, means ± SEM).**<italic toggle="yes">P</italic> &lt; 0.01. (<bold>c</bold>) Schematic figure showing the EREs surrounding the rs62293499 SNP. (<bold>d</bold>) ERα ChIP assay that show SNP‐dependent ERα binding to the EREs region that are upstream from the rs62293499 SNP in LCLs with different genotypes treated with the indicated drugs: androstenedione (A), anastrozole (Ana), and exemestane (Exe) (<italic toggle="yes">n</italic> = 3, means ± SEM). **<italic toggle="yes">P</italic> &lt; 0.01. Statistical test: two‐way ANOVA. ANOVA, analysis of variance; ERE, estrogen response element; LCL, lymphoblastoid cell line; SNP, single‐nucleotide polymorphism.</p>
                  </caption>
                  <graphic xlink:href="CPT-110-1038-g002" position="anchor" id="jats-graphic-9"/>
                </fig>
                <p>We identified 223 genes that were correlated with GPR160 in TCGA ER+ breast cancer data set (<bold>Table </bold>
<xref rid="cpt2311-sup-0001" ref-type="supplementary-material"><bold>S6</bold></xref>, <bold>Figure </bold>
<xref rid="cpt2311-sup-0001" ref-type="supplementary-material"><bold>S7</bold></xref>
<bold>a</bold>), enriched in metabolic, PI3K‐AKT, and MAPK signaling pathways. GPR160 knockdown resulted in the downregulation of cell proliferation pathway, such as PI3K‐AKT (<bold>Figure </bold>
<xref rid="cpt2311-sup-0001" ref-type="supplementary-material"><bold>S7</bold></xref>
<bold>b</bold>).</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="cpt2311-sec-0018">
              <title>DISCUSSION</title>
              <p>In the present investigation, we evaluated the interaction between genetic variation and 2 AIs, exemestane and anastrozole, on BCFI in the MA.27 clinical trial in which postmenopausal women with resected early‐stage breast cancer were treated with anastrozole or exemestane adjuvant therapy (<bold>Figure </bold>
<xref rid="cpt2311-fig-0001" ref-type="fig"><bold>1a</bold></xref>). The SNPs identified in the interaction analysis were analyzed for their association with BCFI in the treatment‐specific cohort (<bold>Figure </bold>
<xref rid="cpt2311-fig-0001" ref-type="fig"><bold>1b,c</bold></xref>), as well as in the combined cohort using our pervious GWAS results.<xref rid="cpt2311-bib-0014" ref-type="bibr"><sup>14</sup></xref> This approach allowed the identification of genetic variants that have a differential effect on BCFI between the two AIs (<bold>Figure </bold>
<xref rid="cpt2311-fig-0001" ref-type="fig"><bold>1d</bold></xref>). The SNPs that interacted with treatments were otherwise lost in the BCFI analysis when the GWAS was adjusted for the treatment arms (<bold>Figure </bold>
<xref rid="cpt2311-fig-0001" ref-type="fig"><bold>1e</bold></xref>, <bold>Table </bold>
<xref rid="cpt2311-sup-0003" ref-type="supplementary-material"><bold>S2</bold></xref>). Our study has provided additional evidence of potential differences among the third‐generation AIs given differences in individual genetic background. We identified an SNP‐based model (<bold>Table </bold>
<xref rid="cpt2311-sup-0001" ref-type="supplementary-material"><bold>S3</bold></xref>, <bold>Figure </bold>
<xref rid="cpt2311-fig-0001" ref-type="fig"><bold>1f</bold></xref>) as a biomarker signature panel for predicting superiority in efficacy between anastrozole and exemestane in a given patient. Our current study only focused on White patients because we only had nine patients from Asian or African decedents who have developed a breast event. In the future, it needs to extend these genetic biomarkers to other ethnicities.</p>
              <p>Support for the position that anastrozole differs from exemestane is provided by our functional validation studies for the SNPs near the <italic toggle="yes">LY75</italic>
<xref rid="cpt2311-bib-0039" ref-type="bibr"><sup>39</sup></xref> and <italic toggle="yes">GPR160</italic>
<xref rid="cpt2311-bib-0040" ref-type="bibr"><sup>40</sup></xref> genes (Figures <xref rid="cpt2311-fig-0003" ref-type="fig">3a</xref>,<xref rid="cpt2311-fig-0005" ref-type="fig">b</xref> and <xref rid="cpt2311-fig-0005" ref-type="fig">5a</xref>). Of note, there had been no prior reports of a relationship of either of these genes with AI efficacy or breast cancer risk. The expression of <italic toggle="yes">LY75</italic> in cells with variant <italic toggle="yes">LY75</italic> SNP sequences was dysregulated by exposure to anastrozole, but not exemestane (<bold>Figure </bold>
<xref rid="cpt2311-fig-0003" ref-type="fig"><bold>3c,d</bold></xref>), which was compatible with the association of variant <italic toggle="yes">LY75</italic> SNP with protection from a breast cancer recurrence while subjects were being treated with exemestane, but not anastrozole. We also showed that the SNP regulated <italic toggle="yes">LY75</italic> expression through ERα (<bold>Figure </bold>
<xref rid="cpt2311-fig-0003" ref-type="fig"><bold>3e–j</bold></xref>). We report for the first time a role for the <italic toggle="yes">LY75</italic> gene in controlling breast cancer cellular phenotypes and corresponding metastatic potential (Figures <xref rid="cpt2311-fig-0004" ref-type="fig">4</xref> and <xref rid="cpt2311-fig-0002" ref-type="fig">2b</xref>). These findings also raise the possibility of targeting downstream EMT in combination with a specific AI to increase its sensitivity for future testing. The <italic toggle="yes">GPR160</italic> SNP mediated <italic toggle="yes">GPR160</italic> expression in response to anastrozole, but not exemestane, by regulating ERα binding to EREs (<bold>Figure </bold>
<xref rid="cpt2311-fig-0005" ref-type="fig"><bold>5</bold></xref>). <italic toggle="yes">GPR160</italic> played a role in breast cancer cell growth (<bold>Figure </bold>
<xref rid="cpt2311-sup-0001" ref-type="supplementary-material"><bold>S7</bold></xref>
<bold>b</bold>, <bold>Figure </bold>
<xref rid="cpt2311-fig-0002" ref-type="fig"><bold>2c</bold></xref>).</p>
              <p>Although all three AIs are interchangeable clinically based on large clinical studies, those studies did not consider patient genetic variability for recruitment and stratification. Our study raises the possibility of salvaging specific AI‐treated patients identified to be at increased risk of breast cancer recurrence with a given AI in that they could be switched to an alternative AI. Thus, the genetic markers identified in this study could help select the appropriate AI for a given patient. A limitation of our study is that no other large adjuvant trial of monotherapy with anastrozole and exemestane collected genotyping data is available. However, we have obtained evidence that anastrozole and exemestane have differing efficacy depending on genetic background and have identified an SNP biomarker panel that could potentially be used to select optimal AI for a given patient.</p>
            </sec>
            <sec id="cpt2311-sec-0020">
              <title>FUNDING</title>
              <p>This research was supported in part by NIH grants P50CA116201 (Mayo Clinic Breast Cancer Specialized Program of Research Excellence), U1961388 (The Pharmacogenomics Research Network), U54 GM114838, BCRF‐17‐075 (the Breast Cancer Research Foundation), U10CA77202, R01CA196648, CCS 015469 from the Canadian Cancer Society, the George M. Eisenberg Foundation for Charities, and the Nan Sawyer Breast Cancer Fund.</p>
            </sec>
            <sec sec-type="COI-statement" id="cpt2311-sec-0021">
              <title>CONFLICT OF INTEREST</title>
              <p>M.J.E. reports employment with Bioclassifier, LLC; royalty income from Prosigma/Nanostring; honoraria from Nanostring, Novartis, AstraZeneca, Pfizer, Sermonix, Abbvie; patent interest from Bioclassifier, LLC, Prosigma/PAM50; P.E.G. reports research funding from Amgen. M.P.G. reports consulting roles with Lilly, Bovica, Novartis, Sermonix, Context Pharmaceuticals, and Genomic Health; R.M.W. and L.W. are co‐founders of, and stockholders in OneOme, LLC. All other authors declared no competing interests for this work.</p>
            </sec>
            <sec id="cpt2311-sec-0022">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p>J.C., K.R.K., J.N.I., R.M.W., and L.W. wrote the manuscript. J.C., J.N.I., and L.W. designed the research. J.C., J.N.I., K.R.K., E.E.C., and P.B. performed the research. J.C., J.N.I., K.R.K., E.E.C., P.B., M.J.E., P.E.G., L.E.S., M.P.G., B.G., and H.G. analyzed the data. K.R.K., E.E.C., and P.B. contributed new reagents/analytical tools.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="cpt2311-sup-0001" position="float" content-type="local-data">
                <caption>
                  <p>Supplementary Material</p>
                </caption>
                <media xlink:href="CPT-110-1038-s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="cpt2311-sup-0002" position="float" content-type="local-data">
                <caption>
                  <p>Table S1</p>
                </caption>
                <media xlink:href="CPT-110-1038-s004.xlsx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="cpt2311-sup-0003" position="float" content-type="local-data">
                <caption>
                  <p>Table S2</p>
                </caption>
                <media xlink:href="CPT-110-1038-s001.xlsx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="cpt2311-sup-0004" position="float" content-type="local-data">
                <caption>
                  <p>Table S5</p>
                </caption>
                <media xlink:href="CPT-110-1038-s003.xlsx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="cpt2311-sec-0019">
              <title>ACKNOWLEDGMENTS</title>
              <p>The authors acknowledge the women who participated in the MA.27 clinical trial and provided blood samples used in these analyses.</p>
            </ack>
            <ref-list content-type="cited-references" id="cpt2311-bibl-0001">
              <ref id="cpt2311-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0001"><string-name><surname>Bray</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Ferlay</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Soerjomataram</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Siegel</surname>, <given-names>R.L.</given-names></string-name>, <string-name><surname>Torre</surname>, <given-names>L.A.</given-names></string-name> &amp; <string-name><surname>Jemal</surname>, <given-names>A.</given-names></string-name>
<article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J. Clin.</source>
<volume>68</volume>, <fpage>394</fpage>–<lpage>424</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">30207593</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0002"><string-name><surname>Burstein</surname>, <given-names>H.J.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Adjuvant endocrine therapy for women with hormone receptor‐positive breast cancer: American society of clinical oncology clinical practice guideline focused update</article-title>. <source>J. Clin. Oncol.</source><volume>32</volume>, <fpage>2255</fpage>–<lpage>2269</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24868023</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0003"><string-name><surname>Smith</surname>, <given-names>I.E.</given-names></string-name> &amp; <string-name><surname>Dowsett</surname>, <given-names>M.</given-names></string-name>
<article-title>Aromatase inhibitors in breast cancer</article-title>. <source>N. Engl. J. Med.</source>
<volume>348</volume>, <fpage>2431</fpage>–<lpage>2442</lpage> (<year>2003</year>).<pub-id pub-id-type="pmid">12802030</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0004"><string-name><surname>Baum</surname>, <given-names>M.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer: results of the ATAC (arimidex, tamoxifen alone or in combination) trial efficacy and safety update analyses</article-title>. <source>Cancer</source><volume>98</volume>, <fpage>1802</fpage>–<lpage>1810</lpage> (<year>2003</year>).<pub-id pub-id-type="pmid">14584060</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0005"><collab collab-type="authors">Breast International Group (BIG) 1‐98 Collaborative group</collab><italic toggle="yes">et al</italic>. <article-title>A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer</article-title>. <source>N. Engl. J. Med.</source><volume>353</volume>, <fpage>2747</fpage>–<lpage>2757</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">16382061</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0006"><string-name><surname>Coombes</surname>, <given-names>R.C.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer</article-title>. <source>N. Engl. J. Med.</source><volume>350</volume>, <fpage>1081</fpage>–<lpage>1092</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15014181</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0007"><collab collab-type="authors">Early Breast Cancer Trialists' Collaborative Group</collab>
. <article-title>Aromatase inhibitors versus tamoxifen in early breast cancer: patient‐level meta‐analysis of the randomised trials</article-title>. <source>Lancet</source>
<volume>386</volume>, <fpage>1341</fpage>–<lpage>1352</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26211827</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0008"><string-name><surname>Geisler</surname>, <given-names>J.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels</article-title>. <source>Clin. Cancer Res.</source><volume>14</volume>, <fpage>6330</fpage>–<lpage>6335</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18829517</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0009"><string-name><surname>Smith</surname>, <given-names>I.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor‐positive, node‐positive early breast cancer: final results of the randomized phase III femara versus anastrozole clinical evaluation (FACE) trial</article-title>. <source>J. Clin. Oncol.</source><volume>35</volume>, <fpage>1041</fpage>–<lpage>1048</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28113032</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0010"><string-name><surname>Goss</surname>, <given-names>P.E.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27–a randomized controlled phase III trial</article-title>. <source>J. Clin. Oncol.</source><volume>31</volume>, <fpage>1398</fpage>–<lpage>1404</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23358971</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0011"><string-name><surname>De Placido</surname>, <given-names>S.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine‐sensitive breast cancer (FATA‐GIM3): a randomised, phase 3 trial</article-title>. <source>Lancet Oncol.</source><volume>19</volume>, <fpage>474</fpage>–<lpage>485</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29482983</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0012"><string-name><surname>Ingle</surname>, <given-names>J.N.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Anastrozole has an association between degree of estrogen suppression and outcomes in early breast cancer and is a ligand for estrogen receptor alpha</article-title>. <source>Clin. Cancer Res.</source><volume>26</volume>, <fpage>2986</fpage>–<lpage>2996</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32098767</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0013"><string-name><surname>Cairns</surname>, <given-names>J.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action</article-title>. <source>Science</source><volume>5(16)</volume>, e137571 (<year>2020</year>). <pub-id pub-id-type="doi">10.1172/jci.insight.137571</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0014"><string-name><surname>Ingle</surname>, <given-names>J.N.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Genetic polymorphisms in the long noncoding RNA MIR2052HG offer a pharmacogenomic basis for the response of breast cancer patients to aromatase inhibitor therapy</article-title>. <source>Cancer Res.</source><volume>76</volume>, <fpage>7012</fpage>–<lpage>7023</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27758888</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0015"><string-name><surname>Cairns</surname>, <given-names>J.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>The lncRNA MIR2052HG regulates ERalpha levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1</article-title>. <source>Breast Cancer Res.</source><volume>21</volume>, <fpage>47</fpage> (<year>2019</year>).<pub-id pub-id-type="pmid">30944027</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0016"><string-name><surname>Ingle</surname>, <given-names>J.N.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Genome‐wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors</article-title>. <source>J. Clin. Oncol.</source><volume>28</volume>, <fpage>4674</fpage>–<lpage>4682</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20876420</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0017"><string-name><surname>Liu</surname>, <given-names>M.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Aromatase inhibitor‐associated bone fractures: a case‐cohort GWAS and functional genomics</article-title>. <source>Mol. Endocrinol.</source><volume>28</volume>, <fpage>1740</fpage>–<lpage>1751</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">25148458</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0018"><string-name><surname>Hudis</surname>, <given-names>C.A.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system</article-title>. <source>J. Clin. Oncol.</source><volume>25</volume>, <fpage>2127</fpage>–<lpage>2132</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17513820</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0019"><string-name><surname>Price</surname>, <given-names>A.L.</given-names></string-name>, <string-name><surname>Patterson</surname>, <given-names>N.J.</given-names></string-name>, <string-name><surname>Plenge</surname>, <given-names>R.M.</given-names></string-name>, <string-name><surname>Weinblatt</surname>, <given-names>M.E.</given-names></string-name>, <string-name><surname>Shadick</surname>, <given-names>N.A.</given-names></string-name> &amp; <string-name><surname>Reich</surname>, <given-names>D.</given-names></string-name>
<article-title>Principal components analysis corrects for stratification in genome‐wide association studies</article-title>. <source>Nat. Genet.</source>
<volume>38</volume>, <fpage>904</fpage>–<lpage>909</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16862161</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0020"><string-name><surname>Patterson</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Price</surname>, <given-names>A.L.</given-names></string-name> &amp; <string-name><surname>Reich</surname>, <given-names>D.</given-names></string-name>
<article-title>Population structure and Eigen analysis</article-title>. <source>PLoS Genet.</source>
<volume>2</volume>, <elocation-id>e190</elocation-id> (<year>2006</year>).<pub-id pub-id-type="pmid">17194218</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0021"><string-name><surname>Purcell</surname>, <given-names>S.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>PLINK: a tool set for whole‐genome association and population‐based linkage analyses</article-title>. <source>Am. J. Hum. Genet.</source><volume>81</volume>, <fpage>559</fpage>–<lpage>575</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17701901</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0022"><string-name><surname>Price</surname>, <given-names>A.L.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Long‐range LD can confound genome scans in admixed populations</article-title>. <source>Am. J. Hum. Genet.</source><volume>83</volume>, <fpage>132</fpage>–<lpage>135</lpage> (<year>2008</year>), author reply 135–139.<pub-id pub-id-type="pmid">18606306</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0023"><string-name><surname>Zhu</surname>, <given-names>Z.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets</article-title>. <source>Nat. Genet.</source><volume>48</volume>, <fpage>481</fpage>–<lpage>487</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27019110</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0024"><collab collab-type="authors">GTEx Consortium</collab>
. <article-title>The Genotype‐Tissue Expression (GTEx) pilot analysis</article-title>. <source>Science</source>
<volume>348</volume>, <fpage>648</fpage>–<lpage>660</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25954001</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0025"><string-name><surname>Cairns</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Ingle</surname>, <given-names>J.N.</given-names></string-name>, <string-name><surname>Wickerham</surname>, <given-names>L.D.</given-names></string-name>, <string-name><surname>Weinshilboum</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>M.</given-names></string-name> &amp; <string-name><surname>Wang</surname>, <given-names>L.</given-names></string-name>
<article-title>SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ERalpha‐positive breast cancer through regulation of BRCA1</article-title>. <source>PLoS Genet.</source>
<volume>13</volume>, <elocation-id>e1007031</elocation-id> (<year>2017</year>).<pub-id pub-id-type="pmid">28968398</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0026"><string-name><surname>Hanson</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Cairns</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>L.</given-names></string-name> &amp; <string-name><surname>Sinha</surname>, <given-names>S.</given-names></string-name>
<article-title>Principled multi‐omic analysis reveals gene regulatory mechanisms of phenotype variation</article-title>. <source>Genome Res.</source>
<volume>28</volume>, <fpage>1207</fpage>–<lpage>1216</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29898900</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0027"><string-name><surname>Cairns</surname>, <given-names>J.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>A network‐based phenotype mapping approach to identify genes that modulate drug response phenotypes</article-title>. <source>Sci. Rep.</source><volume>6</volume>, <fpage>37003</fpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27841317</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0028"><string-name><surname>Niu</surname>, <given-names>N.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Radiation pharmacogenomics: a genome‐wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines</article-title>. <source>Genome Res.</source><volume>20</volume>, <fpage>1482</fpage>–<lpage>1492</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20923822</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0029"><string-name><surname>Ingle</surname>, <given-names>J.N.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention</article-title>. <source>Cancer Discov.</source><volume>3</volume>, <fpage>812</fpage>–<lpage>825</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23764426</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0030"><string-name><surname>Wang</surname>, <given-names>W.Y.</given-names></string-name>, <string-name><surname>Barratt</surname>, <given-names>B.J.</given-names></string-name>, <string-name><surname>Clayton</surname>, <given-names>D.G.</given-names></string-name> &amp; <string-name><surname>Todd</surname>, <given-names>J.A.</given-names></string-name>
<article-title>Genome‐wide association studies: theoretical and practical concerns</article-title>. <source>Nat. Rev. Genet.</source>
<volume>6</volume>, <fpage>109</fpage>–<lpage>118</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15716907</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0031"><string-name><surname>Lachance</surname>, <given-names>J.</given-names></string-name><article-title>Disease‐associated alleles in genome‐wide association studies are enriched for derived low frequency alleles relative to HapMap and neutral expectations</article-title>. <source>BMC Med. Genomics</source><volume>3</volume>, <fpage>57</fpage> (<year>2010</year>).<pub-id pub-id-type="pmid">21143973</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0032"><collab collab-type="authors">Cancer Genome Atlas Network</collab>
. <article-title>Comprehensive molecular portraits of human breast tumours</article-title>. <source>Nature</source>
<volume>490</volume>, <fpage>61</fpage>–<lpage>70</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">23000897</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0033"><string-name><surname>Ciriello</surname>, <given-names>G.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Comprehensive molecular portraits of invasive lobular breast cancer</article-title>. <source>Cell</source><volume>163</volume>, <fpage>506</fpage>–<lpage>519</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26451490</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0034"><string-name><surname>Yu</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Pardoll</surname>, <given-names>D.</given-names></string-name> &amp; <string-name><surname>Jove</surname>, <given-names>R.</given-names></string-name>
<article-title>STATs in cancer inflammation and immunity: a leading role for STAT3</article-title>. <source>Nat. Rev. Cancer</source>
<volume>9</volume>, <fpage>798</fpage>–<lpage>809</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19851315</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0035"><string-name><surname>Sullivan</surname>, <given-names>N.J.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Interleukin‐6 induces an epithelial‐mesenchymal transition phenotype in human breast cancer cells</article-title>. <source>Oncogene</source><volume>28</volume>, <fpage>2940</fpage>–<lpage>2947</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19581928</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0036"><string-name><surname>Yadav</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Kumar</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Datta</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Teknos</surname>, <given-names>T.N.</given-names></string-name> &amp; <string-name><surname>Kumar</surname>, <given-names>P.</given-names></string-name>
<article-title>IL‐6 promotes head and neck tumor metastasis by inducing epithelial‐mesenchymal transition via the JAK‐STAT3‐SNAIL signaling pathway</article-title>. <source>Mol. Cancer Res.</source>
<volume>9</volume>, <fpage>1658</fpage>–<lpage>1667</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21976712</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0037"><string-name><surname>Gong</surname>, <given-names>C.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Abnormally expressed JunB transactivated by IL‐6/STAT3 signaling promotes uveal melanoma aggressiveness via epithelial‐mesenchymal transition</article-title>. <source>Biosci. Rep.</source><volume>38</volume>(<issue>4</issue>), <fpage>BSR20180532</fpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29899166</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0038"><string-name><surname>Kalluri</surname>, <given-names>R.</given-names></string-name> &amp; <string-name><surname>Weinberg</surname>, <given-names>R.A.</given-names></string-name>
<article-title>The basics of epithelial‐mesenchymal transition</article-title>. <source>J. Clin. Invest.</source>
<volume>119</volume>, <fpage>1420</fpage>–<lpage>1428</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19487818</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0039"><string-name><surname>East</surname>, <given-names>L.</given-names></string-name> &amp; <string-name><surname>Isacke</surname>, <given-names>C.M.</given-names></string-name>
<article-title>The mannose receptor family</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>1572</volume>, <fpage>364</fpage>–<lpage>386</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">12223280</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2311-bib-0040">
                <label>40</label>
                <mixed-citation publication-type="journal" id="cpt2311-cit-0040"><string-name><surname>Regard</surname>, <given-names>J.B.</given-names></string-name>, <string-name><surname>Sato</surname>, <given-names>I.T.</given-names></string-name> &amp; <string-name><surname>Coughlin</surname>, <given-names>S.R.</given-names></string-name>
<article-title>Anatomical profiling of G protein‐coupled receptor expression</article-title>. <source>Cell</source>
<volume>135</volume>, <fpage>561</fpage>–<lpage>571</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18984166</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
